Literature DB >> 9058652

Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives.

G Harvey1, C Black, P Maddison, N McHugh.   

Abstract

OBJECTIVE: To study the prevalence and specificity of antinucleolar antibodies (ANoA) in patients with systemic sclerosis (SSc), their spouses, and their first-degree relatives, and to investigate whether SSc family members have greater frequency of ANoA than expected.
METHODS: The sera of 58 SSc probands, 4 first-degree relatives with SSc, 215 first-degree relatives without SSc, and 24 spouses were screened for ANoA by indirect immunofluorescence (IF), and nucleolar antigens were characterized by immunoprecipitation (IP) of 35S methionine labeled K562 cell extracts. Sera from 118 randomly chosen family members without SSc were separately compared with 120 age and sex matched blood donor controls.
RESULTS: Antinucleolar reactivity was detected by IF in 25 patients with SSc (40.3%), in 33 non-SSc relatives (15.3%), and in 4 spouses (16.7%). Twenty-four sera had autoantibodies to defined nucleolar antigens by IP (seven Pm-Scl, ten RNA polymerase (pol) I, four U3 RNP, three Th RNP), and all were from patients with SSc (38.7%). No serum had more than one type of nucleolar-specific autoantibody. Four sera had autoantibodies to topoisomerase I (topo I) and RNA pol II, one of which also recognized RNA pol I and RNA pol III. Antinucleolar IF was significantly more common in the unaffected first-degree relatives of patients with SSc (18.1%) than in controls (8.3%; p < 0.05). A small number of sera from both relatives and controls recognized bands by IP, none of which was identified as a SSc-specific autoantigen.
CONCLUSION: Although antinucleolar reactivity is more common in the first-degree relatives of patients with SSc than controls, SSc associated ANoA are only present in patients with the disease, and appear to be mutually exclusive.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058652

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  When to stop in the quest of formes frustes of connective tissue disease?

Authors:  Vincent Cottin; Jean-Christophe Lega; Nicole Fabien; Jean-François Cordier
Journal:  Clin Rheumatol       Date:  2007-01-18       Impact factor: 2.980

2.  Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis.

Authors:  Lisa K Peterson; Troy D Jaskowski; Maureen D Mayes; Anne E Tebo
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.

Authors:  G R Harvey; S Butts; A L Rands; Y Patel; N J McHugh
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 4.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

Review 5.  Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.

Authors:  Alfred Grassegger; Gabriela Pohla-Gubo; Margret Frauscher; Helmut Hintner
Journal:  Wien Med Wochenschr       Date:  2008

6.  Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients.

Authors:  Hadi Poormoghim; Alireza Salek Moghadam; Maziar Moradi-Lakeh; Mehrzad Jafarzadeh; Behnam Asadifar; Mohsen Ghelman; Elham Andalib
Journal:  Rheumatol Int       Date:  2013-01-24       Impact factor: 2.631

Review 7.  The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications.

Authors:  Sophie P Toya; George E Tzelepis
Journal:  Rheumatol Int       Date:  2009-02-27       Impact factor: 2.631

Review 8.  Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations.

Authors:  John D Reveille
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

9.  Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.

Authors:  Rudolf Mierau; Pia Moinzadeh; Gabriela Riemekasten; Inga Melchers; Michael Meurer; Frank Reichenberger; Michael Buslau; Margitta Worm; Norbert Blank; Rüdiger Hein; Ulf Müller-Ladner; Annegret Kuhn; Cord Sunderkötter; Aaron Juche; Christiane Pfeiffer; Christoph Fiehn; Michael Sticherling; Percy Lehmann; Rudolf Stadler; Eckhard Schulze-Lohoff; Cornelia Seitz; Ivan Foeldvari; Thomas Krieg; Ekkehard Genth; Nicolas Hunzelmann
Journal:  Arthritis Res Ther       Date:  2011-10-21       Impact factor: 5.156

Review 10.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.